Int. J. Clin. Biomed. Sci. 1-2 (2026) 95-105

Contents lists available at AcademiansEdu

International Journal of Clinical and Biomedical Sciences
ISSN:3141-3145
journal homepage: https://academiansedu.org/ijcbs/

The Convergence of Data, Discovery, and Delivery: An Integrated Examination of Artificial Intelligence, Pharmacology Education, Preclinical Modeling, and Microbiome Therapeutics in Modern Healthcare

Anas Hif*

[1]*Department of Haematology, University College Hospital, Nigeria*

ARTICLE INFO

Article history:
Received 27 March 2026
Received in revised form
20 April 2026
Accepted 10 May 2026
Available online 9 June 2026

Keywords:
artificial intelligence, public health informatics, clinical pharmacology education, three-dimensional cell culture, tumor spheroids

ABSTRACT

The contemporary healthcare and pharmaceutical landscape is undergoing a profound transformation driven by the convergence of four interrelated domains: artificial intelligence-enabled public health surveillance, clinical pharmacology education, advanced preclinical modeling systems, and microbiome-based therapeutics. This paper presents an integrative analysis of recent research across these domains, synthesizing findings from studies on public health informatics, clinical pharmacology curriculum development, three-dimensional tumor spheroid technologies, and the gut microbiome dependency continuum in drug discovery. The analysis reveals that while each domain has advanced independently, their convergence offers unprecedented opportunities for improving healthcare delivery, drug development efficiency, and patient outcomes. Key findings include: (1) AI and machine learning applications in public health, including satellite imagery for community identification and natural language processing for infectious disease surveillance, demonstrate significant potential but face persistent challenges in translation from proof-of-concept to real-world adoption; (2) The development of standardized clinical pharmacology and therapeutics curricula across Europe, achieved through modified Delphi methodology, provides a blueprint for harmonizing medical education and improving prescribing competencies; (3) Three-dimensional multicellular tumor spheroids represent a critical advancement in preclinical modeling, bridging the gap between oversimplified two-dimensional systems and resource-intensive in vivo studies, with the proposed Pharmacological Relevance Index offering a framework for standardizing model characterization; (4) The gut microbiome functions as a dynamic metabolic interface that transforms xenobiotics, produces bioactive metabolites, and regulates host physiology, with the Gut Microbiome Dependency Continuum providing a unified framework spanning from ecosystem-dependent interventions to fully engineered microbial therapeutics. This paper argues that the integration of these domains—data science, education, preclinical modeling, and microbiome science—represents a paradigm shift toward predictive, personalized, and participatory healthcare. The implications for clinical practice, health system design, research priorities, and ethical governance are explored, with particular attention to the challenges of standardization, scalability, and equity.

1. Introduction

The practice of medicine and the process of drug discovery stand at a crossroads unlike any in history. Three decades into the twenty-first century, healthcare systems and pharmaceutical research face intersecting challenges: the rising burden of chronic and complex diseases, the imperative to improve patient safety and outcomes, the need for more predictive and physiologically relevant preclinical models, and the recognition that the human microbiome functions as a critical determinant of drug efficacy and toxicity. These challenges are accompanied by unprecedented opportunities: the availability of vast quantities of health data, advances in artificial intelligence and machine learning, the development of sophisticated three-dimensional culture systems, and the emergence of engineered microbial therapeutics.

The integration of artificial intelligence into public health practice represents one of the most significant developments in recent years. As documented in the International Medical Informatics Association (IMIA) Yearbook selections for 2020 and 2021, researchers have leveraged satellite imagery and deep learning to identify remote communities in low-income countries, developed near real-time global infectious disease surveillance systems using natural language processing, and created early-warning systems for suicide attempts using electronic health records (Cossin & Thiebaut, 2020; Diallo & Bordea, 2021). These applications demonstrate the potential of AI to address pressing public health challenges, yet the transition from proof-of-concept to real-world adoption remains a persistent difficulty.

Parallel to these developments in public health informatics, the field of clinical pharmacology and therapeutics education has undergone significant transformation. Brinkman et al. (2018) documented a marked variation in the quantity and quality of clinical pharmacology education across European medical schools, with final-year medical students demonstrating poor prescribing competencies. The modified Delphi study conducted by the European Association for Clinical Pharmacology and Therapeutics achieved consensus on 252 key learning outcomes that should be included in undergraduate curricula to ensure that European graduates can prescribe safely and effectively. This effort represents a crucial step toward harmonizing medical education and improving patient safety.

At the preclinical level, the development of three-dimensional multicellular tumor spheroids has emerged as a transformative approach to drug discovery and toxicology. As reviewed by Furtuna et al. (2026), traditional two-dimensional monolayer cultures fail to recapitulate the biochemical, mechanical, and architectural complexity of solid tumors, leading to a persistent disconnect between preclinical success and clinical efficacy. Spheroids provide a physiologically relevant model that mimics essential characteristics of the tumor microenvironment, including oxygen and nutrient diffusion gradients, extracellular matrix signaling, and barriers to drug penetration. The rapid expansion of spheroid technologies—ranging from scaffold-free aggregation methods to microfluidic tumor-on-a-chip platforms and bioprinted architectures—has created a heterogeneous landscape that requires systematic characterization and standardization.

The gut microbiome has emerged as perhaps the most transformative frontier in pharmacology. Habtemariam (2026) proposed the Gut Microbiome Dependency Continuum, a four-layer framework describing progressively deeper levels of microbiome involvement in drug discovery and therapeutic function. This framework spans from ecosystem-dependent interventions such as faecal microbiota transplantation, through microbiome-modulated approved drugs including metformin and irinotecan, to microbiota-transformable natural products and fully engineered microbial therapeutics. The recognition that microbial metabolism functions as an independent and sometimes dominant determinant of drug outcomes has fundamentally challenged traditional pharmacological paradigms.

This paper undertakes an integrated examination of these four domains—AI-enabled public health surveillance, clinical pharmacology education, three-dimensional preclinical modeling, and microbiome therapeutics—to illuminate their convergence and to identify the principles that should guide their development. The central argument is that the future of healthcare and drug discovery lies not in the dominance of any single technology or approach but in their thoughtful integration, guided by ethical commitment to patient-centeredness, equity, and the restoration of function and dignity.

2. Literature Review

2.1 Artificial Intelligence and Public Health Informatics

The integration of artificial intelligence into public health informatics has accelerated dramatically, driven by advances in machine learning, the proliferation of health data, and the imperative to improve population health outcomes. Cossin and Thiebaut (2020) documented the evolution of the field toward "Public Health Data Science," characterized by the increasing use of novel data sources—satellite imagery, news media, social media, and electronic health records—combined with sophisticated analytical methods.

The use of internet data for disease surveillance, or infodemiology, has been a particularly active area of research. Studies have employed search engine queries, social media posts, and news media to monitor influenza activity, track physical activity levels, and detect outbreaks of plague, conjunctivitis, and other infectious diseases (Bragazzi & Mahroum, 2019; Deiner et al., 2019). The development of a global infectious disease activity database by Feldman et al. (2019), using natural language processing, machine learning, and human expertise, exemplifies the potential of these approaches. The system analyzed news in 65 languages and detected 94% of outbreaks before they were reported by the World Health Organization, with a mean lead time of 43.4 days.

A particularly innovative application of AI to public health is the use of satellite imagery and machine learning to identify remote communities and facilitate access to health services. Bruzelius et al. (2019) demonstrated that satellite-based neural network methods could automate the identification of communities in rural areas of low-income countries, detecting 75% of registered communities and identifying additional communities not previously captured in census data. This approach has the potential to facilitate greater targeting of health services and reduce inequalities in healthcare access.

The 2021 IMIA Yearbook, as reported by Diallo and Bordea (2021), highlighted additional applications of AI to public health challenges. Zheng et al. (2020) developed an early-warning system for suicide attempts using deep learning and electronic health records, identifying 117 significant features including age groups, mental health conditions, pain, and psychotropic medication use. Roope et al. (2020) employed a randomized design to test the impact of fear-based messages, with and without empowering self-management elements, on

patient consultations and antibiotic requests. Degeling et al. (2020) used community juries to assess perceptions of technologically enhanced communicable disease surveillance systems, finding strong support under current research governance structures.

2.2 Clinical Pharmacology and Therapeutics Education

The education of medical students in clinical pharmacology and therapeutics has been identified as a critical determinant of prescribing competency and patient safety. Brinkman et al. (2018) documented that prescribing is a complex and challenging task that requires knowledge, skills, and attitudes acquired through systematic education and training. Studies throughout Europe have demonstrated that recent graduates are responsible for a large number of prescribing errors and report having little confidence in their prescribing skills.

The modified Delphi study conducted by Brinkman et al. (2018) achieved consensus among 129 experts from 27 European countries on 252 key learning outcomes for undergraduate clinical pharmacology and therapeutics education. These outcomes were organized into 34 subcategories, including 192 knowledge outcomes, 47 skills outcomes, and 13 attitudes outcomes. The study identified that most outcomes (80%) should be acquired during the clinical years of the medical curriculum, with 13% during the preclinical years and 7% during both phases. The authors provided a blueprint for an integrated context-based learning European core curriculum, describing when and how the outcomes might be taught and assessed.

The importance of educational interventions in improving prescribing competencies was further demonstrated by Ansari et al. (2026), who conducted a three-day interactive workshop on clinical pharmacology and therapeutics for medical students before starting internship. The study found a significant improvement in test scores from a pre-test mean of 5.47 ± 1.9 to a post-test mean of 7.63 ± 1.75 ($p < 0.01$). The authors concluded that educational interventions like interactive workshops can help improve prescribing competencies and decrease medication errors.

2.3 Three-Dimensional Preclinical Modeling

Two-dimensional monolayer cultures have long been the standard preclinical system in anticancer drug discovery, yet their oversimplified structure fails to recapitulate the biochemical, mechanical, and architectural complexity of solid tumors. Furtuna et al. (2026) reviewed recent advances in three-dimensional multicellular tumor spheroids, highlighting their ability to mimic essential characteristics of the tumor microenvironment, including oxygen and nutrient diffusion gradients, extracellular matrix remodeling, spatially stratified proliferation, and barriers to drug penetration.

The technologies for spheroid generation have expanded rapidly between 2021 and 2025. Scaffold-free approaches, including hanging-drop methods and ultra-low-attachment plates, dominate early-stage research due to their simplicity and compatibility with high-throughput workflows. Microwell arrays provide superior geometric control and reduce variability across experiments. Scaffold-based approaches, including hydrogels and collagen matrices, introduce exogenous extracellular matrices that supply biochemical cues and biomechanical properties more closely resembling in vivo tumor tissue. Microfluidic tumor-on-a-chip platforms incorporate perfusable channels that simulate vascular physiology, including shear stress, directional flow, and dynamic drug perfusion. Bioprinting technologies enable precise spatial patterning of cells, spheroids, and extracellular matrix components.

The pharmacological applications of tumor spheroids are extensive. Furtuna et al. (2026) documented their use in dose-response studies, nanomedicine evaluation, chemoresistance modeling, immuno-oncology research, and patient-derived tumor spheroid-based precision medicine. In toxicology, spheroids enable organ-specific safety assessment, long-term exposure studies, and alignment with the 3R principles (replace, reduce, refine) by reducing animal use. The authors proposed the Pharmacological Relevance Index, a multidimensional descriptive framework that captures the conceptual and translational significance of spheroid models by integrating cellular complexity, extracellular matrix context, geometric control, analytical throughput, translational linkage, and toxicological breadth.

2.4 The Gut Microbiome in Drug Discovery

The human gut microbiome has emerged as a key determinant of drug efficacy, toxicity, and bioavailability. Habtemariam (2026) proposed the Gut Microbiome Dependency Continuum, a four-layer framework describing progressively deeper levels of microbiome involvement in drug discovery and therapeutic function. The first layer, intact functional microbiome-dependent therapeutics, includes interventions such as faecal microbiota transplantation and defined microbial consortia. The second layer, microbiome-modulated approved drugs, includes widely used therapeutics whose pharmacokinetics or pharmacodynamics are strongly influenced by microbial metabolism, including metformin, irinotecan, levodopa, and digoxin. The third layer, microbiota-transformable natural products, encompasses dietary and plant-derived compounds such as polyphenols, ginsenosides, alkaloids, fibres, isoflavones, lignans, and glucosinolates. The fourth layer, engineered microbiome therapeutics, includes synthetic biology approaches such as programmable microbial systems, engineered probiotics, CRISPR-based microbiome editing, and microbiome-responsive drug delivery systems.

The evidence for microbiome-dependent drug metabolism is substantial. Metformin, for example, remodels the gut microbial ecosystem, increasing the relative abundance of mucin-degrading and short-chain fatty acid-producing bacteria (Shin et al., 2014). The antidiabetic effects of metformin extend beyond direct activation of host AMP-activated protein kinase to include substantial microbiome-mediated mechanisms (Wu et al., 2017). Similarly, gut microbial β-glucuronidases can deconjugate the glucuronidated form of irinotecan's active metabolite, resulting in local accumulation of the cytotoxic compound and damage to the intestinal epithelium (Wallace et al., 2010). The pharmacokinetics of levodopa are strongly

influenced by gut microbial metabolism, which can reduce systemic drug availability and contribute to inter-individual variability in therapeutic response in Parkinson's disease (Maini Rekdal et al., 2019).

Natural products exhibit extensive dependence on microbial biotransformation. Polyphenols such as rutin require gut microbial metabolism to become bioactive, as intestinal bacteria cleave glycosidic bonds to produce metabolites with greater systemic bioavailability and biological activity (Hanske et al., 2009). Ginsenosides, the major bioactive constituents of Panax species, are triterpenoid saponins with low membrane permeability and poor oral bioavailability that require microbial deglycosylation to generate the bioactive metabolite compound K (Akao et al., 1998). Isoflavones such as daidzein require conversion by specific intestinal bacteria to produce equol, a metabolite with markedly enhanced activity (Setchell et al., 2002). Dietary fibres are metabolized by anaerobic gut bacteria through saccharolytic fermentation pathways, yielding short-chain fatty acids that regulate host lipid metabolism, immune function, and energy homeostasis (den Besten et al., 2013).

Engineered microbiome therapeutics represent the most advanced layer of the continuum. Programmable microbial systems can be constructed with genetic circuits that convert biological inputs into measurable outputs, functioning as living biosensors of host physiology and drug action (Danino et al., 2010). Engineered probiotics such as Escherichia coli Nissle 1917 have been repurposed as in situ drug production and delivery systems, demonstrating the feasibility of using gut-resident bacteria as continuous metabolic therapies (Isabella et al., 2018). CRISPR-based microbiome editing enables precise manipulation of microbial genomes within complex communities, using RNA-guided nucleases to selectively target, modify, or eliminate specific bacterial strains or genes in situ (Bikard et al., 2014). Microbiome-responsive drug delivery systems exploit microbial activity as an endogenous trigger for site-specific drug release, enabling spatially restricted pharmacological activity within the gastrointestinal tract (Sinha & Kumria, 2003). Synthetic microbial consortia with defined functional outputs can be designed to enhance robustness, stability, and therapeutic efficiency through distributed metabolic tasks (Venturelli et al., 2018).

Table 1. Characteristics of the Primary Literature Included in the Integrative Review

Primary Source	Research Design	Main Focus	Major Contribution
IMIA Yearbook 2020	Narrative review of selected studies	Public Health Informatics	AI applications in disease surveillance and population health
IMIA Yearbook 2021	Narrative review of selected studies	Epidemiology Informatics	Machine learning, digital surveillance, public health decision-making
Brinkman et al. (2018)	Modified Delphi Study	Clinical Pharmacology Education	Development of European core curriculum and learning outcomes
Furtuna et al. (2026)	Review Article	3D Tumor Spheroids	Advanced preclinical cancer models and Pharmacological Relevance Index
Habtemariam (2026)	Conceptual Review	Gut Microbiome Pharmacology	Gut Microbiome Dependency Continuum framework

3. Methodology

This paper employs an integrative review methodology, synthesizing findings from multiple sources that represent the state of the art in their respective domains. The primary sources include the 2020 and 2021 IMIA Yearbook sections on Public Health and Epidemiology Informatics, the modified Delphi study on clinical pharmacology and therapeutics education in Europe, the review of three-dimensional tumor spheroids and the Pharmacological Relevance Index, and the Gut Microbiome Dependency Continuum framework.

The integrative review methodology involves several steps: (1) identifying key themes and concepts across the sources; (2) analyzing these themes in relation to the broader literature; (3) synthesizing findings to develop an integrated framework; and (4) identifying implications for research, practice, and policy. This approach is appropriate for examining complex, multidomain phenomena and for generating insights that transcend individual studies.

The study selection process is summarized in Figure 1, which illustrates the identification, screening, eligibility assessment, and final inclusion of the literature synthesized in this integrative review.

Figure 1. PRISMA-Style Flow Diagram of Study Selection



The 2020 IMIA Yearbook selection process, as described by Cossin and Thiebaut (2020), involved a comprehensive literature search using PubMed/MEDLINE, with a focus on public health and epidemiological journal articles published in 2019 that included medical informatics topics. The search returned 835 references, which were reviewed by section editors to select candidate best papers. These papers were then peer-reviewed by external reviewers, with two papers finally selected as best papers.

The 2021 IMIA Yearbook selection process, as described by Diallo and Bordea (2021), followed a similar methodology. A PubMed search of 2020 literature on public health and epidemiology informatics yielded 920 references. The section editors reviewed the references, selected 15 candidate best papers, which were then peer-reviewed by editors and external reviewers. Three papers were finally selected as best papers.

The modified Delphi study by Brinkman et al. (2018) involved a systematic literature search, selection of a European expert panel, development of a web-based questionnaire, and three rounds of rating and revision. A total of 129 experts from 27 European countries participated, with 92 experts (71%) completing all three rounds. Outcomes were included if ≥80% of experts gave them a score of 4 or 5 on a 5-point scale.

The review of three-dimensional tumor spheroids by Furtuna et al. (2026) synthesized recent advances in spheroid generation, characterization, and application across therapeutics, pharmacology, and toxicology. The review examined scaffold-free and scaffold-based approaches, microfluidic technologies, bioprinting strategies, and analytical readouts including high-content confocal microscopy, live imaging, and mass spectrometry imaging.

The Gut Microbiome Dependency Continuum framework by Habtemariam (2026) organized microbiome involvement in drug discovery along a graded spectrum of increasing biological relevance and engineering control. The framework spans from minimal microbial influence on drug action to complete microbiome-mediated dependency, with four conceptual layers: intact functional microbiome-dependent therapeutics, microbiome-modulated approved drugs, microbiota-transformable natural products, and engineered microbiome therapeutics.

4. Results and Integrated Analysis

4.1 The Convergence of Data and Public Health

The findings from the IMIA Yearbook selections demonstrate the transformative potential of AI and data science in public health practice. The global infectious disease surveillance system developed by Feldman et al. (2019) exemplifies the power of integrating diverse data sources—news media, natural language processing, machine learning, and human expertise—to achieve near real-time outbreak detection. The ability to detect outbreaks 43 days earlier than WHO reporting on average represents a significant advance in epidemic preparedness and response. However, the system also highlights important limitations: news reports often fail to distinguish between suspected and confirmed cases and are prone to false positive errors. This underscores the need for hybrid systems that combine automated detection with human verification and integration with traditional surveillance data.

Table 2. Major Applications of AI-Enabled Public Health Informatics

Application	Technology	Healthcare Benefit	Limitation
Disease Surveillance	Machine Learning + NLP	Early outbreak detection	False positives
Community Identification	Satellite Imaging + Deep Learning	Improved access to healthcare	Requires high-quality satellite data
Suicide Risk Prediction	Deep Learning + Electronic Health Records	Early clinical intervention	Limited external validation
Antibiotic	Behavioural	Reduced	Patient

Application	Technology	Healthcare Benefit	Limitation
Stewardship	Analytics	unnecessary prescriptions	behavioural variability
Digital Surveillance	Public Health Data Science	Real-time monitoring	Privacy and governance concerns

The early-warning system for suicide attempts developed by Zheng et al. (2020) demonstrates the application of deep learning to electronic health records for risk stratification. The identification of 117 significant features, including demographic characteristics, mental health conditions, pain, and medication use, provides a foundation for targeted prevention efforts. The use of Local Interpretable Model-agnostic Explanations (LIME) to interpret risk stratification results addresses the critical need for transparency and explainability in AI-based clinical decision support.

The use of satellite imagery and machine learning to identify remote communities, as described by Bruzelius et al. (2019), represents a novel application of data-driven methods to address healthcare access inequalities. By automating the identification of communities in low-income countries where census data is missing, this approach can facilitate the expansion of community health worker programs and improve access to health services. The detection of additional communities not previously identified highlights the potential of this approach to reveal previously unrecognized populations in need of services.

Despite these promising developments, the transition from proof-of-concept to real-world applications and adoption by health authorities remains a persistent challenge. Cossin and Thiebaut (2020) noted that "the transition from proofs of concept to real world applications and adoption by health authorities remains a difficult leap to make." This challenge reflects multiple factors: the need for robust validation across diverse settings, the integration of novel approaches into existing workflows, the requirement for sustainable funding and infrastructure, and the necessity of addressing ethical and privacy concerns.

4.2 Harmonizing Clinical Pharmacology Education

The modified Delphi study by Brinkman et al. (2018) provides a comprehensive blueprint for clinical pharmacology and therapeutics education in Europe. The 252 learning outcomes identified by the expert panel cover knowledge, skills, and attitudes across 34 subcategories, from basic principles of pharmacology to rational prescribing and medication error prevention. The emphasis on skills and attitudes, which were generally considered more important than knowledge outcomes, reflects the recognition that prescribing is a complex cognitive process requiring repeated training and practice.

The finding that most outcomes should be acquired during the clinical years of the medical curriculum highlights the importance of context-based learning in the setting of the future profession. However, the authors also noted that prescribing skills should be taught as early as possible in the curriculum, preferably using simulated and clinical environments with real responsibility for patient care. This tension between early exposure and clinical relevance reflects a broader challenge in medical education: how to balance foundational knowledge with practical application.

The study by Ansari et al. (2026) provides empirical support for the effectiveness of educational interventions in improving prescribing competencies. The significant improvement in test scores following a three-day interactive workshop demonstrates that structured, clinically focused training can enhance knowledge and skills. The authors emphasized the importance of educational theories—behaviorism, cognitivism, and constructivism—in designing effective learning experiences. The use of real-life case scenarios, small group discussions, and active questioning reflects a shift from didactic lectures toward more engaging and effective pedagogical approaches.

The integration of clinical pharmacology education with broader medical curricula remains a challenge. The blueprint proposed by Brinkman et al. (2018) describes an integrated context-based learning approach in which clinical pharmacology and therapeutics is a recurrent theme in modules and attachments throughout the medical curriculum. This approach contrasts with the traditional model of one or two distinct courses and reflects the recognition that prescribing competence develops through repeated exposure and practice across multiple clinical contexts.

4.3 Advancing Preclinical Modeling with Three-Dimensional Systems

The review by Furtuna et al. (2026) demonstrates that multicellular tumor spheroids have become central to modern pharmacology because they reproduce key microenvironmental features—diffusion gradients, cellular heterogeneity, extracellular matrix remodeling—that fundamentally alter drug response compared with two-dimensional systems. The ability of spheroids to develop oxygen gradients, proliferative and quiescent zones, and diffusion-limited drug penetration yields dose-response curves that better match in vivo outcomes.

The technologies for spheroid generation have expanded significantly, ranging from simple scaffold-free methods to sophisticated microfluidic and bioprinted systems. Each approach offers distinct advantages and limitations. Scaffold-free systems such as hanging-drop and ultra-low-attachment plates are accessible, cost-effective, and compatible with high-throughput workflows, but produce spheroids with variable morphology and limited complexity. Scaffold-based systems such as hydrogels and collagen matrices provide more physiologically relevant extracellular matrix cues but introduce additional complexity and variability. Microfluidic tumor-on-a-chip platforms offer dynamic perfusion and real-time imaging but require specialized equipment and expertise. Bioprinting enables precise spatial patterning but faces challenges in bioink optimization and viability maintenance.

The Pharmacological Relevance Index proposed by Furtuna et al. (2026) provides a conceptual framework for characterizing and comparing spheroid models across six dimensions: cellular

complexity, extracellular matrix and biomechanics, geometric control and reproducibility, throughput and analytical compatibility, translational linkage, and toxicological breadth. Unlike numerical scoring systems, the Pharmacological Relevance Index is narrative-based, encouraging researchers to explicitly describe the strengths and limitations of their models and enabling transparent comparison across studies.

The application of spheroids to immuno-oncology research represents a particularly promising frontier. As Furtuna et al. (2026) note, spheroids impose physical, biochemical, and immunosuppressive barriers that immune cells must overcome, providing more realistic assessments of immunotherapy efficacy than two-dimensional systems. Patient-derived tumor spheroids offer the potential for functional precision oncology, where treatment decisions are guided not only by genomic markers but also by direct ex vivo drug sensitivity testing.

Table 3. Comparison of Three-Dimensional Tumor Spheroid Technologies

Technology	Advantages	Limitations	Applications
Hanging Drop Method	Simple and inexpensive	Variable spheroid size	Drug screening
Ultra-Low Attachment Plates	High throughput	Less structural complexity	Pharmacological studies
Hydrogel-Based Models	Mimics extracellular matrix	Expensive	Tumor biology
Microfluidic Tumor-on-Chip	Dynamic perfusion	Specialized equipment	Precision medicine
Bioprinted Spheroids	Precise architecture	Complex fabrication	Personalized oncology

4.4 The Gut Microbiome as a Therapeutic Interface

The Gut Microbiome Dependency Continuum proposed by Habtemariam (2026) provides a unified framework for understanding the diverse roles of the microbiome in drug discovery and therapeutic function. The four layers of the continuum—intact functional microbiome-dependent therapeutics, microbiome-modulated approved drugs, microbiota-transformable natural products, and engineered microbiome therapeutics—capture progressively deeper levels of microbiome involvement, from passive modulation to full engineering control.

The clinical success of faecal microbiota transplantation in recurrent Clostridioides difficile infection exemplifies Layer 1 of the continuum, where therapeutic efficacy is contingent upon the presence of an intact, diverse, and functionally competent microbial ecosystem. The transition from traditional donor stool faecal microbiota transplantation to regulated live biotherapeutic products such as Rebyota and Vowst represents a significant advance in safety, reproducibility, and scalability. The development of defined microbial consortia such as VE303 further demonstrates the shift toward precision microbiome therapeutics, where specific microbial communities are designed based on ecological principles.

Layer 2 of the continuum encompasses widely used approved drugs whose pharmacokinetics or pharmacodynamics are strongly influenced by microbial metabolism. The examples of metformin, irinotecan, levodopa, and digoxin illustrate the diverse mechanisms through which the microbiome modulates drug action, including metabolic transformation, enzymatic activation and inactivation, and competition for metabolic pathways. These findings challenge traditional pharmacological paradigms centered on single-organism or single-target models and position the microbiome as a dynamic determinant of therapeutic outcome.

Layer 3 addresses natural products whose biological activity depends on microbial biotransformation. The extensive evidence for microbiota-dependent metabolism of polyphenols, ginsenosides, alkaloids, dietary fibres, isoflavones, lignans, and glucosinolates demonstrates that the biological effects of diverse dietary and plant-derived compounds emerge from host-microbiome co-metabolism rather than host biology alone. The inter-individual variability in metabolite production, driven by differences in gut microbial composition and enzymatic capacity, explains substantial variation in response to these compounds.

Layer 4 represents the frontier of engineered microbiome therapeutics, including programmable microbial systems, engineered probiotics, CRISPR-based microbiome editing, microbiome-responsive drug delivery systems, and synthetic microbial consortia. These approaches range from living biosensors that detect and record physiological signals to engineered probiotics that produce therapeutic molecules in situ to CRISPR-based systems that selectively modify microbial genomes within complex communities. The progression toward engineered systems reflects a shift from pharmacology in the host to pharmacology within a coupled host-microbiome system.

Table 4. Gut Microbiome Dependency Continuum and Representative Therapeutic Applications

Continuum Layer	Description	Representative Examples	Clinical Significance
Layer 1	Intact microbiome-dependent therapeutics	Faecal microbiota transplantation, Live biotherapeutic products	Restoration of microbial ecosystems
Layer 2	Microbiome-modulated approved drugs	Metformin, Irinotecan, Digoxin, Levodopa	Drug efficacy and toxicity influenced by gut microbes
Layer 3	Microbiota-transformable natural products	Polyphenols, Ginsenosides, Isoflavones	Microbial metabolism enhances bioavailability

Continuum Layer	Description	Representative Examples	Clinical Significance
Layer 4	Engineered microbiome therapeutics	Engineered probiotics, CRISPR microbiome editing, Synthetic microbial consortia	Precision medicine and targeted drug delivery

4.5 Integration Across Domains

The convergence of AI-enabled public health surveillance, clinical pharmacology education, three-dimensional preclinical modeling, and microbiome therapeutics reveals several common themes and principles. First, the importance of **systematic characterization and standardization** is evident across all domains. The Pharmacological Relevance Index for spheroids, the structured learning outcomes for clinical pharmacology education, and the Gut Microbiome Dependency Continuum all provide frameworks for organizing and communicating complex information, enabling comparison across studies and supporting evidence-based decision-making.

Second, the need for **integration of multiple disciplines and perspectives** is essential for progress. AI-enabled public health surveillance requires collaboration between data scientists, epidemiologists, and public health practitioners. Clinical pharmacology education benefits from input from clinical pharmacologists, medical educators, and junior doctors. Three-dimensional preclinical modeling requires expertise in cell biology, materials science, and pharmacology. Microbiome therapeutics require knowledge of microbiology, synthetic biology, and clinical medicine. The integration of these diverse perspectives is essential for developing effective, scalable, and ethically sound interventions.

Third, the challenge of **translation from proof-of-concept to real-world application** recurs across domains. The IMIA Yearbook reviews highlight the difficulty of moving from research demonstrations to adoption by health authorities. The implementation of standardized clinical pharmacology curricula faces barriers in already overcrowded medical curricula. The adoption of three-dimensional culture systems in drug discovery requires changes in established workflows and regulatory acceptance. The clinical translation of engineered microbiome therapeutics faces regulatory, ecological, and biosafety challenges. Addressing these translation challenges requires sustained investment, robust validation, and engagement with stakeholders.

Fourth, the importance of **ethical considerations** is paramount across domains. AI-enabled surveillance raises concerns about privacy, bias, and equity. Clinical pharmacology education must address the ethical dimensions of prescribing, including patient autonomy, informed consent, and shared decision-making. Three-dimensional preclinical modeling raises questions about the appropriate use of animal models and the 3R principles. Microbiome therapeutics raise ethical issues related to data privacy, informed consent, and equitable access. Addressing these ethical dimensions requires ongoing dialogue, transparent governance, and commitment to patient-centeredness.

Figure 2. Integrated Framework Linking Artificial Intelligence, Clinical Pharmacology, Preclinical Modeling, and Microbiome Therapeutics in Modern Healthcare



Figure 2. Conceptual framework illustrating the convergence of artificial intelligence, clinical pharmacology education, advanced preclinical modeling, and gut microbiome therapeutics. The integration of these complementary domains supports precision medicine, accelerates drug discovery, and contributes to improved patient outcomes and healthcare innovation.

5. Discussion

5.1 Implications for Clinical Practice

The integration of AI-enabled surveillance, improved pharmacology education, advanced preclinical modeling, and microbiome therapeutics has profound implications for clinical practice. Physicians must develop competencies in data science and digital health alongside traditional clinical skills. They must be able to interpret AI-generated recommendations, engage patients in shared decision-making, and coordinate care across multidisciplinary teams. They must also maintain the humanistic values of medicine—empathy, compassion, and respect for patient autonomy—in an increasingly technological environment.

Clinical pharmacology education must continue to evolve to prepare medical graduates for the challenges of safe prescribing in complex, multimorbid populations. The learning outcomes identified by Brinkman et al. (2018) provide a foundation for curriculum development, but implementation requires institutional commitment, faculty development, and robust assessment structures. The integration of prescribing skills training throughout the medical curriculum, using simulated and clinical environments with real responsibility for patient care, is essential for developing competence and confidence.

The application of three-dimensional culture systems in clinical practice is most advanced in the context of patient-derived tumor spheroids for functional precision oncology. As Furtuna et al. (2026) note, patient-derived tumor spheroids preserve key attributes of the patient tumor, including genetic heterogeneity, epigenetic memory, and patient-specific stromal interactions, enabling direct ex vivo drug sensitivity testing. This approach has the potential to reduce ineffective treatments and accelerate personalized therapy planning, though challenges remain regarding standardization, turnaround time, and integration with clinical workflows.

The clinical translation of microbiome therapeutics is progressing rapidly, with FDA-approved products for recurrent Clostridioides difficile infection and emerging applications in metabolic, inflammatory, and neuroimmune disorders. Physicians must be aware of the potential for microbiome modulation to influence drug efficacy and toxicity, and they should consider microbiome status when selecting and dosing medications. The recognition that microbial metabolism can activate, inactivate, toxify, or detoxify pharmaceutical agents has implications for drug selection, dosing, and monitoring.

5.2 Implications for Health Systems

Health systems must invest in the infrastructure needed for AI-enabled surveillance and clinical decision support: electronic health records, data interoperability standards, privacy-preserving analytics platforms, and digital literacy programs. They must address the digital divide through targeted interventions for underserved populations. They must develop governance frameworks that ensure AI is used ethically, transparently, and accountably.

Health systems must strengthen clinical pharmacology and therapeutics education as a component of undergraduate and postgraduate medical training. This requires investment in faculty development, educational resources, and assessment structures. It also requires integration of prescribing competencies into licensing and certification processes, as exemplified by the UK Prescribing Safety Assessment and the Dutch National Pharmacotherapy Assessment.

Health systems must support the adoption of advanced preclinical modeling systems in drug discovery and development. This includes investment in research infrastructure, training for researchers, and regulatory frameworks that recognize the validity of three-dimensional culture systems for safety and efficacy assessment. The Pharmacological Relevance Index provides a framework for communicating model characteristics to regulators and other stakeholders.

Health systems must integrate microbiome science into clinical practice and drug development. This includes investment in microbiome research, development of clinical microbiome diagnostics, and regulatory frameworks for microbiome therapeutics. The Gut Microbiome Dependency Continuum provides a framework for understanding the diverse roles of the microbiome in drug action and for guiding the development of microbiome-informed therapeutics.

5.3 Implications for Research

Research must address the gaps in AI-enabled public health surveillance, including the transition from proof-of-concept to real-world adoption, the integration of multiple data sources, the development of robust validation methods, and the assessment of implementation barriers and facilitators. Studies must examine the effectiveness of AI-enabled interventions in diverse populations and settings, with attention to issues of bias, equity, and privacy.

Research must evaluate the effectiveness of clinical pharmacology education interventions in improving prescribing competencies and reducing medication errors. Longitudinal studies are needed to assess the retention of knowledge and skills over time and the translation of educational gains into clinical practice. Comparative effectiveness studies should identify which educational methods and curricula are most effective in different contexts.

Research must advance the development and application of three-dimensional culture systems in drug discovery and toxicology. This includes improving the reproducibility and scalability of spheroid production, developing standardized protocols for characterization and analysis, and validating spheroid models against clinical outcomes. The Pharmacological Relevance Index provides a framework for reporting model characteristics, but empirical studies are needed to establish the relationship between model features and predictive validity.

Research must deepen understanding of microbiome-drug interactions and their clinical implications. This includes identifying the microbial enzymes and pathways responsible for drug metabolism, characterizing the factors that determine inter-individual variability in microbial metabolic capacity, and developing strategies for modulating microbial metabolism to improve therapeutic outcomes. The Gut Microbiome Dependency Continuum provides a framework for organizing research questions and guiding the development of microbiome-informed therapeutics.

5.4 Ethical Considerations

The convergence of AI, pharmacology education, preclinical modeling, and microbiome therapeutics raises profound ethical questions. Algorithmic bias can perpetuate and amplify health disparities. Data privacy and security concerns can undermine patient trust. The digital divide can exclude vulnerable populations from the benefits of technological innovation. The dominance of pharmaceutical industry funding can distort research priorities.

These ethical challenges require a comprehensive response. Ethical frameworks must be embedded in the design, development, and deployment of AI systems. Regulatory frameworks must be adapted to govern AI's expanding role in medicine. Equity must be a central principle guiding investment, innovation, and implementation. Patients must be engaged as partners in research and governance. The humanistic values of medicine—empathy, compassion, and

respect for patient autonomy—must be preserved and strengthened.

The microbiome raises additional ethical considerations. The collection and analysis of microbiome data raises privacy and consent issues. The manipulation of microbial communities raises questions about ecological and evolutionary consequences. The commercialization of microbiome therapeutics raises concerns about access and equity. Addressing these ethical dimensions requires ongoing dialogue among researchers, clinicians, patients, and the public.

5.5 Limitations and Future Directions

Several limitations of this integrative analysis should be acknowledged. The synthesis of findings from diverse sources, each with its own methodology and context, requires careful interpretation. The generalizability of findings across settings and populations remains to be established. The translation of research findings into practice faces multiple barriers that may not be fully captured in the literature.

Future research should address these limitations through several directions. Longitudinal studies could examine the evolution of AI-enabled surveillance systems, pharmacology education programs, preclinical modeling technologies, and microbiome therapeutics over time. Comparative effectiveness studies could identify the optimal approaches for different contexts and populations. Implementation studies could identify barriers and facilitators to adoption and scale-up. Interdisciplinary research could address the integration of these domains and the development of comprehensive frameworks for healthcare transformation.

6. Conclusion

This integrative analysis has examined the convergence of four transformative developments in healthcare and drug discovery: AI-enabled public health surveillance, clinical pharmacology education, three-dimensional preclinical modeling, and microbiome therapeutics. The findings reveal that while each domain has advanced independently, their convergence offers unprecedented opportunities for improving healthcare delivery, drug development efficiency, and patient outcomes.

The integration of AI into public health practice has demonstrated significant potential for disease surveillance, risk stratification, and targeted intervention, yet the transition from proof-of-concept to real-world adoption remains a persistent challenge. The harmonization of clinical pharmacology education across Europe through the identification of key learning outcomes provides a blueprint for improving prescribing competencies and patient safety. The development of three-dimensional culture systems has advanced preclinical modeling, bridging the gap between oversimplified two-dimensional systems and resource-intensive in vivo studies. The recognition of the gut microbiome as a dynamic metabolic interface has fundamentally challenged traditional pharmacological paradigms, opening new avenues for precision therapeutics and engineered microbial systems.

Several principles emerge from this integrated analysis. The importance of systematic characterization and standardization is evident across domains, enabling comparison across studies and supporting evidence-based decision-making. The need for integration of multiple disciplines and perspectives is essential for progress, requiring collaboration among data scientists, clinicians, educators, and researchers. The challenge of translation from proof-of-concept to real-world application requires sustained investment, robust validation, and engagement with stakeholders. The importance of ethical considerations, including privacy, equity, and patient-centeredness, must guide the development and deployment of innovations.

The future of healthcare and drug discovery lies at the convergence of data, discovery, and delivery—where powerful analytical tools are harnessed to understand disease, develop effective interventions, and deliver them equitably. Achieving this vision will require sustained investment in research, infrastructure, and workforce development; ongoing attention to ethical and regulatory frameworks; and a deep commitment to the values of equity, participation, and patient-centeredness that have always been central to medicine. By embracing the integration of these domains, we can build healthcare systems that not only save lives but also restore them to fullness, meaning, and purpose.

References

Akao, T., Kida, H., Kanaoka, M., Hattori, M., & Kobashi, K. (1998). Intestinal bacterial hydrolysis is required for the appearance of compound K in rat plasma after oral administration of ginsenoside Rb1 from Panax ginseng. *Journal of Pharmacy and Pharmacology, 50*(10), 1155-1160.

Ansari, A., Shivasakthy, M., & Hasan, K. (2026). Impact of a clinical pharmacology and therapeutics workshop on prescription errors among medical interns. *International Journal of Drug Delivery Technology, 16*(2), 599-606.

Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nature Biotechnology, 32*(11), 1146-1150.

Bragazzi, N. L., & Mahroum, N. (2019). Google Trends predicts present and future plague cases during the plague outbreak in Madagascar: Infodemiological study. *JMIR Public Health and Surveillance, 5*(1), e13142.

Brinkman, D. J., Tichelaar, J., Mokkink, L. B., Christiaens, T., Likic, R., Maciulaitis, R., Costa, J., Sanz, E. J., Maxwell, S. R., Richir, M. C., & van Agtmael, M. A. (2018). Key learning outcomes for clinical pharmacology and therapeutics education in Europe: A modified Delphi study. *Clinical Pharmacology & Therapeutics, 104*(2), 317-325.

Bruzelius, E., Le, M., Kenny, A., Downey, J., Danieletto, M., Baum, A., Doupe, P., Silva, B., Landrigan, P. J., & Singh, P. (2019). Satellite images and machine learning can identify remote communities to facilitate access to health services. *Journal of the American Medical Informatics Association, 26*(8-9), 806-812.

Cossin, S., & Thiebaut, R. (2020). Public health and epidemiology informatics: Recent research trends moving toward public health data science. *Yearbook of Medical Informatics, 29*(1), 231-234.

Danino, T., Mondragon-Palomino, O., Tsimring, L., & Hasty, J. (2010). A synchronized quorum of genetic clocks. *Nature, 463*(7279), 326-330.

Degeling, C., Carter, S. M., van Oijen, A. M., McAnulty, J., Sintchenko, V., Braunack-Mayer, A., Yarwood, T., Johnson, J., & Gilbert, G. L. (2020). Community perspectives on the benefits and risks of technologically enhanced

communicable disease surveillance systems: A report on four community juries. *BMC Medical Ethics, 21*(1), 31.

Deiner, M. S., McLeod, S. D., Wong, J., Chodosh, J., Lietman, T. M., & Porco, T. C. (2019). Google searches and detection of conjunctivitis epidemics worldwide. *Ophthalmology, 126*(9), 1219-1229.

den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D. J., & Bakker, B. M. (2013). The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. *Journal of Lipid Research, 54*(9), 2325-2340.

Diallo, G., & Bordea, G. (2021). Public health and epidemiology informatics: Recent research trends. *Yearbook of Medical Informatics, 30*(1), 280-282.

Feldman, J., Thomas-Bachli, A., Forsyth, J., Patel, Z. H., & Khan, K. (2019). Development of a global infectious disease activity database using natural language processing, machine learning, and human expertise. *Journal of the American Medical Informatics Association, 26*(11), 1355-1359.

Furtuna, M. M., & Mungiu, O. C. (2026). Multicellular tumor spheroids: Bridging the gap between preclinical models and clinical translation in pharmacology and toxicology. *Therapeutics, Pharmacology and Clinical Toxicology, 24*(1), 1-19.

Habtemariam, S. (2026). The gut microbiome dependency continuum in drug discovery: A unified pharmacology framework linking clinical drugs, natural products, and engineered microbial therapeutics. *Pharmaceuticals, 19*(5), 1-39.

Hanske, L., Loh, G., Sczesny, S., Blaut, M., & Braune, A. (2009). The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats. *Journal of Nutrition, 139*(6), 1095-1102.

Isabella, V. M., Ha, B. N., Castillo, M. J., Lubkowicz, D. J., Rowe, S. E., Millet, Y. A., Anderson, C. L., Li, N., Fisher, A. B., West, K. A., Reeder, P. J., Momin, M. M., Bergeron, C. G., Guilmain, S. E., Miller, P. F., Kurtz, C. B., & Falb, D. (2018). Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. *Nature Biotechnology, 36*(9), 857-864.

Maini Rekdal, V., Bess, E. N., Bisanz, J. E., Turnbaugh, P. J., & Balskus, E. P. (2019). Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. *Science, 364*(6445), eaau6323.

Roope, L. S. J., Tonkin-Crine, S., Herd, N., Michie, S., Pouwels, K. B., Castro-Sanchez, E., Sallis, A., Hopkins, S., Robotham, J. V., Crook, D. W., Peto, T., Peters, M., Butler, C. C., Walker, A. S., & Wordsworth, S. (2020). Reducing expectations for antibiotics in primary care: A randomised experiment to test the response to fear-based messages about antimicrobial resistance. *BMC Medicine, 18*(1), 110.

Setchell, K. D., Brown, N. M., & Lydeking-Olsen, E. (2002). The clinical importance of the metabolite equol—A clue to the effectiveness of soy and its isoflavones. *Journal of Nutrition, 132*(12), 3577-3584.

Shin, N. R., Lee, J. C., Lee, H. Y., Kim, M. S., Whon, T. W., Lee, M. S., & Bae, J. W. (2014). An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut, 63*(5), 727-735.

Sinha, V. R., & Kumria, R. (2003). Microbially triggered drug delivery to the colon. *European Journal of Pharmaceutical Sciences, 18*(1), 3-18.

Venturelli, O. S., Carr, A. C., Fisher, G., Hsu, R. H., Lau, R., Bowen, B. P., Hromada, S., Northen, T., & Arkin, A. P. (2018). Deciphering microbial interactions in synthetic human gut microbiome communities. *Molecular Systems Biology, 14*(6), e8157.

Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L. A., Mani, S., & Redinbo, M. R. (2010). Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science, 330*(6005), 831-835.

Wu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., Xifra, G., Mercader, J. M., Torrents, D., Burcelin, R., Ricart, W., Perkins, R., Fernàndez-Real, J. M., & Bäckhed, F. (2017). Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. *Nature Medicine, 23*(7), 850-858.

Zheng, L., Wang, O., Hao, S., Ye, C., Liu, M., Xia, M., Sabo, A. L., Markovic, L., Stearns, F., Kanov, L., Sylvester, K. L., Widen, R., McElhinney, D. B., Zhang, W., Liao, J., & Ling, X. B. (2020). Development of an early-warning system for high-risk patients for suicide attempt using deep learning and electronic health records. *Translational Psychiatry, 10*(1), 72.